Skip to main
  1. Stocks
  2. PolyPid
  3. Forecast
PYPD

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid is viewed favorably because D-PLEX100 has replicated strong Phase 3 efficacy, cutting incisional surgical-site infections by about 60% in SHIELD II, while the NDA is already under Priority Review with a November 28, 2026 PDUFA date and no filing issues. The Azurity partnership materially derisks commercialization by providing $30M already paid, potential additional milestones of over $290M, tiered mid-teen to mid-20s royalties, and manufacturing/supply economics, all while avoiding the cost of building a U.S. sales force. Fundamental upside is further supported by a capital-light balance sheet with runway into 2028, potential NTAP reimbursement from October 1, 2027 to improve hospital economics, and optionality from broader colorectal labeling, Europe, and the Kynatrix platform.

Bears say

PolyPid is viewed negatively because its investment case is still anchored to a single product, D-PLEX100, which remains under FDA review with a November 28, 2026 PDUFA date and still faces CRL, additional-study, or labeling risk after a failed Ph3 history. Manufacturing execution in Israel, possible FDA inspection or validation issues, and reliance on Azurity for commercialization create layered uncertainty, while hospital-by-hospital adoption, slow P&T reviews, and a potential NTAP denial could keep penetration and near-term revenue weak. Financially, the setup also looks fragile: royalties, supply revenue, and milestone timing are undisclosed, launch economics are back-end weighted, the June 2025 warrant overhang adds dilution risk, and any delay could force additional dilutive financing.

PolyPid (PYPD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

PolyPid (PYPD) Analyst Forecast & Price Prediction

Get the latest PolyPid (PYPD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PolyPid (PYPD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Nov 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


PolyPid (PYPD) Analyst Forecast & Price Prediction

Get the latest PolyPid (PYPD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PolyPid (PYPD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PYPD stock data and trends